Aimmune Therapeutics, Inc. (AIMT) Receives Consensus Rating of “Buy” from Brokerages
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has been given a consensus rating of “Buy” by the six research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $46.75.
AIMT has been the subject of several recent analyst reports. Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a research note on Thursday, July 27th. Zacks Investment Research upgraded Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 target price for the company in a research note on Wednesday, November 8th. Wedbush restated an “ourperform” rating and set a $42.00 target price on shares of Aimmune Therapeutics in a research note on Monday, August 14th. Credit Suisse Group raised their target price on Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a research note on Monday, October 23rd. Finally, BidaskClub downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th.
In other news, insider Susan E. Barrowcliffe sold 18,390 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $22.00, for a total transaction of $404,580.00. Following the transaction, the insider now owns 3,223 shares of the company’s stock, valued at $70,906. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mary M. Rozenman sold 30,000 shares of the stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $22.50, for a total transaction of $675,000.00. Following the transaction, the insider now directly owns 30,129 shares in the company, valued at approximately $677,902.50. The disclosure for this sale can be found here. Insiders have sold 317,720 shares of company stock worth $8,400,244 in the last ninety days. Corporate insiders own 24.56% of the company’s stock.
Hedge funds have recently modified their holdings of the company. SG Americas Securities LLC lifted its position in shares of Aimmune Therapeutics by 10.1% during the second quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 499 shares during the last quarter. Legal & General Group Plc lifted its holdings in Aimmune Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 1,634 shares during the last quarter. Voya Investment Management LLC lifted its holdings in Aimmune Therapeutics by 31.2% in the second quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock worth $324,000 after acquiring an additional 3,757 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in Aimmune Therapeutics in the second quarter worth about $333,000. Finally, American International Group Inc. lifted its holdings in Aimmune Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock worth $352,000 after acquiring an additional 1,070 shares during the last quarter. 72.42% of the stock is currently owned by institutional investors and hedge funds.
Shares of Aimmune Therapeutics (AIMT) opened at $35.28 on Friday. Aimmune Therapeutics has a 52 week low of $15.97 and a 52 week high of $37.50.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.09. analysts forecast that Aimmune Therapeutics will post -2.63 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/aimmune-therapeutics-inc-aimt-receives-consensus-rating-of-buy-from-brokerages/1708374.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.